Join        Login             Stock Quote

Neurocrine Biosciences (NBIX) Pipeline Will Drive Upside In 2012, Initiated As 'Buy': Deutsche Bank

 March 17, 2012 02:08 PM

Deutsche Bank (DB) initiated coverage of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a developer of drugs to treat neurological and endocrine-related diseases, with a "Buy" rating and price target of $15.

The banks believes upside this year will be driven by increased investor confidence in the company's VMAT2 and Elagolix products in uterine fibroids. Currently shares reflect only value to Elagolix in endometriosis & zero to pipeline, DB said.

Elagolix has been shown effective in reducing pain and bleeding in 3 endometriosis phase 2 studies. DB models greater that $1 billion in worldwide sales. "Assigning a 75 percent probability of success in phase 3, we get to an NPV for Elagolix in endometriosis of $7," the bank wrote.

[Related -Sector Detector: Bulls Sucking Wind In Late Push To Close Year Positive]

"We do not see much risk to owning NBIX in 2012 as the Elagolix ph3 in endometriosis trial reads out in 2014. The phase 3 trial for Elagolix in endo must show statistical significance on pain & bleeding for approval," DB wrote.

The bank is of the view that investors are assigning no value to NBI-98854, a wholly-owned VMAT2 inhibitor for tardive dyskinesia (TD), despite approval AHEAD of Elagolix. "Six-week Phase 2 placebo controlled data in YE12 will likely increase investor confidence. We see a high likelihood of success as another VMAT2 inhibitor, TBZ, has shown to be effective & have a durable response in TD," the bank said.

The stock ended Friday's regular trading at $8.51. Over the past year, shares have been trading between $5.42 and $9.98.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageLong-term Relationships and Credit Scores

Unlike many commentators, I tend to think credit scores are a good read on...

article imageIn Defense Of Rolling Return Charts

Robeco’s Lukas Daalder has a bit of an issue with rolling-performance graphics. Bashing a recent chart of read on...

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Bears On The Run
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.